Registration Dossier

Administrative data

Description of key information

Several acute oral studies and a dermal toxicity study are available for 1,4-dihydroxyanthraquinone. No study is available for acute inhalation toxicity. This does not need to be conducted according REACH Annex VII column 2 because valid studies for acute oral and dermal toxicity are on hand.

Key value for chemical safety assessment

Acute toxicity: via oral route

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
discriminating dose
Value:
5 000 mg/kg bw
Quality of whole database:
The materials/methods and results are described in detail and are sufficient for evaluation.

Acute toxicity: via inhalation route

Endpoint conclusion
Endpoint conclusion:
no study available

Acute toxicity: via dermal route

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
discriminating dose
Value:
2 500 mg/kg bw
Quality of whole database:
The materials/methods and results are described in detail and are sufficient for evaluation.

Additional information

In 3 valid acute oral toxicity studies a LD50 > 5000 mg/kg bw was found. None of the animals died at a single oral dose of 5000 mg/kg bw. In the acute dermal toxicity study the highest applied dose was 2500 mg/kg bw. None of the animals died after application of 2500 mg 1,4-dhihydroxyanthraquinone.


Justification for classification or non-classification

In 3 valid acute oral toxicity studies a LD50 > 5000 mg/kg bw was found. None of the animals died at a single oral dose of 5000 mg/kg bw. In the acute dermal toxicity study the highest applied dose was 2500 mg/kg bw. None of the animals died after application of 2500 mg 1,4-dhihydroxyanthraquinone.

According to CLP classification criteria (Regulation (EC) No 1272/2008) a classification is therefore not justified.